TAVR Patient Screening & Identification Guide

Transcription

1 TAVR Patient Screening & Identification Guide

2 Severe Aortic Stenosis is Life Threatening Patients may live with aortic stenosis for many years during a latent, asymptomatic period, even before symptoms of the disease develop and present. However, after patients begin experiencing symptoms, it is urgent they receive treatment. Average Course for Adults with Valvular Aortic Stenosis 1 100% Onset Severe Symptoms 80% Angina Survival, % 60% 40% Latent Period (Increasing Obstruction, Myocardial Overload) Syncope Failure % Average Survival, years Age, years

3 Treatment is Critical 50 % After the onset of symptoms, patients with severe aortic stenosis have a survival rate as low as 50% at 2 years and 20% at 5 years without aortic valve replacement. 2 1 YEAR 2 YEARS

4 Aortic Stenosis Progression Healthy Mild Moderate Severe

5 Guidelines for Aortic Valve Replacement in Patients with Aortic Stenosis Aortic Stenosis Severe High Gradient Severe Low Flow/Low Gradient At Risk/Progressive AVA Typically 1.0 cm 2 Vmax 4 m/s or P mean 40 mmhg AVA 1.0 cm 2 with resting aortic Vmax < 4 m/s or P mean < 40 mmhg AVA Typically > 1.0 cm 2 Vmax < 4 m/s Symptomatic (stage D1) Symptomatic LVEF < 50% Repeat echo every 6-12 months YES NO YES NO Should be recommended for valve replacement Exercise test demonstrating decreased exercise tolerance or a fall in systolic BP Reasonable to recommend for valve replacement Dobutamine stress echo (DSE) with AVA 1 cm 2 and Vmax 4 m/s (stage D2) AVA 1 cm 2 and LVEF 50% (stage D3*) Reasonable to recommend for valve replacement Worsening signs or symptoms Increased flow restrictions AVA < 1.0 cm 2 and/or Vmax 4 m/s Consider for severe aortic stenosis evaluation *AVR should be considered with stage D3 AS only if valve obstruction is the most likely cause of symptoms, stroke volume index is < 35 ml/m 2, indexed AVA is 0.6 cm 2 /m 2, and data are recorded when the patient is normotensive (systolic BP < 140 mmhg).

6 Transcatheter Aortic Valve Replacement (TAVR) The TAVR procedure can be performed through multiple access approaches; however, the most common approach is the transfemoral approach. In the transfemoral approach, the valve is delivered via a catheter through the femoral artery.

7 TAVR Patient Profile Your patient may be considered a potential TAVR candidate if: They have symptomatic heart disease due to severe native calcific aortic stenosis AND The Heart Team determines that the patient has predicted risk of surgical mortality 3% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by STS risk calculator

8 The PARTNER II trial was a robust, rigorous clinical study in more than 3,000 intermediate-risk patients. TAVR with the SAPIEN 3 valve demonstrated 75% lower rates of 30-day mortality and disabling stroke compared to surgery. The PARTNER II Trial Intermediate-Risk Data All-cause Mortality All-cause Mortality, % % Surgery (PARTNER IIA trial) TAVR with SAPIEN 3 valve (PARTNER II S3i trial) 13.0% 7.4% % days Months No. at risk: Surgery SAPIEN 3 TAVR 1,077 1,043 1, The PARTNER II trial intermediate-risk cohort 30-day unadjusted clinical event rates for TAVR with the SAPIEN 3 valve, AT population (n=1,077). The PARTNER II trial intermediate-risk cohort unadjusted clinical event rates, AT population.

9 Disabling Stroke 40 Surgery (PARTNER IIA trial) TAVR with SAPIEN 3 valve (PARTNER II S3i trial) Disabling Stroke, % % 1.0% % 2.3% 3 30 days Months No. at risk: Surgery SAPIEN 3 TAVR ,077 1,033 1, The PARTNER II trial intermediate-risk cohort unadjusted clinical event rates, AT population.

10 Understanding Risk Assessment An evaluation of the possible risks for each individual patient should be performed if intervention is contemplated. Factors such as the risk of operative mortality, patient frailty, major organ system compromise, other major comorbidities and procedure-specific impediments must be taken into consideration. Predictive Risk of Operative Mortality The STS risk model calculator predicts the risk of operative mortality and morbidity after adult cardiac surgery on the basis of patient demographics and clinical variables. Frailty The standard assessment of frailty includes the following four components: Activities of Daily Living, independence in - feeding - bathing - dressing - ambulating - toileting - hygiene Serum Albumin Level Grip Strength Gait Speed Major Organ System Compromise Cardiac severe LV systolic or diastolic dysfunction or RV dysfunction, fixed pulmonary hypertension CKD stage 3 or worse ( 45 GFR) Pulmonary dysfunction with FEV1 < 50% or DLCO2 < 50% of predicted CNS dysfunction GI dysfunction Cancer active malignancy Liver any history of cirrhosis, variceal bleeding, or elevated INR in the absence of VKA therapy

11 Intermediate or Greater Risk TAVR Patients May Present with Some of the Following Reduced EF History of renal insufficiency Prior CABG History of syncope Prior open chest surgery History of CAD History of AFib Prior chest radiation History of stroke/cva History of COPD Peripheral vascular disease Diabetes and hypertension Old age Heavily calcified aorta Fatigue, slow gait Frailty

12 Logistics of Patient Assessment for TAVR The Heart Team confirms the patient meets the treatment indication by conducting a series of additional tests. Patient with severe aortic stenosis is identified by referring physician. Patient is referred to TAVR Center. An evaluation of the cardiac morphology and function of the valve is completed using transthoracic echocardiography. The aortic valvular complex and peripheral vasculature are evaluated using MDCT.

13 Cardiac catheterization is performed in order to assess if coronary intervention is needed. Multidisciplinary review is conducted and treatment plan is recommended by the Heart Team. If the Heart Team determines that the patient meets the indication for TAVR, devising a treatment plan is a collaborative decision between the referring physician, Heart Team, patient and patient s family. The above is a suggested flow for the patient screening process, however, the order in which screening tests are conducted varies depending on the patient s profile and should be at the discretion of the Heart Team.

14 The Specialized Heart Team Approach at a TAVR Center The Heart Team at a TAVR Center is composed of a multidisciplinary, collaborative group of physicians and caregivers, including interventional cardiologists, cardiothoracic surgeons, imaging specialists, anesthesiologists and valve clinic coordinators. This cohesive, multi-disciplinary approach embodies optimal patient centric care, dedication across medical specialties and a collaborative treatment decision. Imaging Specialists Interventional Cardiologist Heart Team Cardiac Surgeon Valve Clinic Coordinator Referring Cardiologist Nursing Anesthesiologist

15 Devising the Treatment Plan The Heart Team will conduct a comprehensive evaluation to determine whether the TAVR procedure is appropriate. Obtain information required to make a recommendation for the best plan of care All potential treatment options are discussed with the patient and caregivers Treatment choice is a collaborative decision between the physicians, patient, and patient s family Severe Symptomatic Aortic Valve Stenosis TAVR Center Surgery TAVR Medical Therapy

16 See Important Safety Information inside pocket. Visit NewHeartValve.com/hcp to download or order educational materials at no charge. References 1. Lester S, Heibron B, Dodek A, Gin K, Jue J. The Natural History and Rate of Progression of Aortic Stenosis. Chest. 1998; 113(4): Otto CM. Timing of aortic valve surgery. Heart. 2000;84: CAUTION: Federal (United States) law restricts this device to sale by or on the order of a physician. Edwards, Edwards Lifesciences, the stylized E logo, NewHeartValve.com and NewHeartValve.com design logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners Edwards Lifesciences Corporation. All rights reserved. PP--US-1325 v1.0 Edwards Lifesciences One Edwards Way, Irvine CA USA edwards.com

17 Important Safety Information Edwards SAPIEN 3 Transcatheter Heart Valve with the Edwards Commander Delivery System Indications: The Edwards SAPIEN 3 transcatheter heart valve, model 9600TFX, and accessories are indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a Heart Team, including a cardiac surgeon, to be at intermediate or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality 3% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator). Contraindications: The valve and delivery systems are contraindicated in patients who cannot tolerate an anticoagulation/antiplatelet regimen or who have active bacterial endocarditis or other active infections. Warnings: Observation of the pacing lead throughout the procedure is essential to avoid the potential risk of pacing lead perforation. There may be an increased risk of stroke in transcatheter aortic valve replacement procedures, as compared to balloon aortic valvuloplasty or other standard treatments in high or greater risk patients. The devices are designed, intended, and distributed for single use only. Do not resterilize or reuse the devices. There are no data to support the sterility, nonpyrogenicity, and functionality of the devices after reprocessing. Incorrect sizing of the valve may lead to paravalvular leak, migration, embolization, and/or annular rupture. Accelerated deterioration of the valve may occur in patients with an altered calcium metabolism. Prior to delivery, the valve must remain hydrated at all times and cannot be exposed to solutions other than its shipping storage solution and sterile physiologic rinsing solution. Valve leaflets mishandled or damaged during any part of the procedure will require replacement of the valve. Caution should be exercised in implanting a valve in patients with clinically significant coronary artery disease. Patients with pre-existing mitral valve devices should be carefully assessed prior to implantation of the valve to ensure proper valve positioning and deployment. Do not mishandle the delivery system or use it if the packaging or any components are not sterile, have been opened or are damaged (e.g., kinked or stretched), or if the expiration date has elapsed. Use of excessive contrast media may lead to renal failure. Measure the patient s creatinine level prior to the procedure. Contrast media usage should be monitored. Patient injury could occur if the delivery system is not un-flexed prior to removal. Care should be exercised in patients with hypersensitivities to cobalt, nickel, chromium, molybdenum, titanium, manganese, silicon, and/or polymeric materials. The procedure should be conducted under fluoroscopic guidance. Some fluoroscopically guided procedures are associated with a risk of radiation injury to the skin. These injuries may be painful, disfiguring, and long-lasting. Valve recipients should be maintained on anticoagulant/antiplatelet therapy, except when contraindicated, as determined by their physician. This device has not been tested for use without anticoagulation. Precautions: Long-term durability has not been established for the valve. Regular medical follow-up is advised to evaluate valve performance. Glutaraldehyde may cause irritation of the skin, eyes, nose, and throat. Avoid prolonged or repeated exposure to, or breathing of, the solution. To maintain proper valve leaflet coaptation, do not overinflate the deployment balloon. Appropriate antibiotic prophylaxis is recommended post-procedure in patients at risk for prosthetic valve infection and endocarditis. Safety, effectiveness, and durability have not been established for valve-in-valve procedures. Safety and effectiveness have not been established for patients with the following characteristics/comorbidities: noncalcified aortic annulus; severe ventricular dysfunction with ejection fraction < 20%; congenital unicuspid or congenital bicuspid aortic valve; mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation > 3+); preexisting prosthetic heart valve or prosthetic ring in any position; severe mitral annular calcification (MAC), severe (> 3+) mitral insufficiency, or Gorlin syndrome; blood dyscrasias defined as leukopenia (WBC < 3000 cells/ml), acute anemia (Hb < 9 g/dl), thrombocytopenia (platelet count < 50,000 cells/ml), or history of bleeding diathesis or coagulopathy; hypertrophic cardiomyopathy with or without obstruction (HOCM); echocardiographic evidence of intracardiac mass, thrombus, or vegetation; a known hypersensitivity or contraindication to aspirin, heparin, ticlopidine (Ticlid), or clopidogrel (Plavix), or sensitivity to contrast media, which cannot be adequately premedicated; significant aortic disease, including abdominal aortic or thoracic aneurysm defined as maximal luminal diameter 5 cm or greater, marked tortuosity (hyperacute bend), aortic arch atheroma (especially if thick [> 5 mm], protruding, or ulcerated) or narrowing (especially with calcification and surface irregularities) of the abdominal or thoracic aorta, severe unfolding and tortuosity of the thoracic aorta; access characteristics that would preclude safe placement of 14F or 16F Edwards esheath introducer set, such as severe obstructive calcification, severe tortuosity, or diameter less than 5.5 mm or 6 mm, respectively; or bulky calcified aortic valve leaflets in close proximity to coronary ostia. Potential Adverse Events: Potential risks associated with the overall procedure including potential access complications associated with standard cardiac catheterization, balloon valvuloplasty, the potential risks of conscious sedation and/or general anesthesia, and the use of angiography: death; stroke/transient ischemic attack, clusters, or neurological deficit; paralysis; permanent disability; respiratory insufficiency or respiratory failure; hemorrhage requiring transfusion or intervention; cardiovascular injury including perforation or dissection of vessels, ventricle, myocardium, or valvular structures that may require intervention; pericardial effusion or cardiac tamponade; embolization including air, calcific valve material, or thrombus; infection including septicemia and endocarditis; heart failure; myocardial infarction; renal insufficiency or renal failure; conduction system defect which may require a permanent pacemaker; arrhythmia; retroperitoneal bleed; arteriovenous (AV) fistula or pseudoaneurysm; reoperation; ischemia or nerve injury; restenosis; pulmonary edema; pleural effusion; bleeding; anemia; abnormal lab values (including electrolyte imbalance); hypertension or hypotension; allergic reaction to anesthesia, contrast media, or device materials; hematoma; syncope; pain or changes at the access site; exercise intolerance or weakness; inflammation; angina; heart murmur; and fever. Additional potential risks associated with the use of the valve, delivery system, and/or accessories include: cardiac arrest; cardiogenic shock; emergency cardiac surgery; cardiac failure or low cardiac output; coronary flow obstruction/ transvalvular flow disturbance; device thrombosis requiring intervention; valve thrombosis; device embolization; device migration or malposition requiring intervention; valve deployment in unintended location; valve stenosis; structural valve deterioration (wear, fracture, calcification, leaflet tear/tearing from the stent posts, leaflet retraction, suture line disruption of components of a prosthetic valve, thickening, stenosis); device degeneration; paravalvular or transvalvular leak; valve regurgitation; hemolysis; device explants; nonstructural dysfunction; mechanical failure of delivery system and/or accessories; and non-emergent reoperation. Edwards Crimper Indications: The Edwards Crimper is indicated for use in preparing the Edwards SAPIEN 3 transcatheter heart valve for implantation. Contraindications: There are no known contraindications. Warnings: The devices are designed, intended, and distributed for single use only. Do not resterilize or reuse the devices. There is no data to support the sterility, nonpyrogenicity, and functionality of the devices after reprocessing. Precautions: For special considerations associated with the use of the Edwards Crimper prior to valve implantation, refer to the Edwards SAPIEN 3 transcatheter heart valve Instructions for Use. Potential Adverse Events: There are no known potential adverse events associated with the Edwards Crimper. CAUTION: Federal (United States) law restricts these devices to sale by or on the order of a physician. Edwards, Edwards Lifesciences, the stylized E logo, Edwards Commander, Edwards esheath, Edwards SAPIEN, Edwards SAPIEN 3, esheath, SAPIEN, SAPIEN 3, and TFX are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners Edwards Lifesciences Corporation. All rights reserved. PP--US-1265 v1.0 Edwards Lifesciences One Edwards Way, Irvine CA USA edwards.com